# US 2018/0022783 A1 · Neisseria meningitidis compositions and methods thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022783 A1
- Document ID: US20180022783A1
- Status: Published application
- Kind: A1
- Application number: 15/728,610
- Filed: 2017-10-10
- Published: 2018-01-25
- Earliest claimed: 2013-09-08
- Assignees: Pfizer Inc.
- Applicants: Pfizer Inc.
- Inventors: Annaliesa Sybil Anderson; Rasappa Gounder Arumugham; John Erwin Farley; Leah Diane Fletcher; Shannon Lea Harris; Kathrin Ute Jansen; Thomas Richard Jones; Lakshmi Khandke; Bounthon Loun; John Lance Perez; Gary Warren Zlotnick
- Web page: https://patentgrep.com/patent/US20180022783A1

## CPC

- C07K 14/22: from Neisseriaceae (F)
- A61K 39/0016: {Combination vaccines based on diphtheria-tetanus-pertussis}
- A61K 39/095: Neisseria
- A61K 39/12: Viral antigens
- A61K 39/13: Poliovirus
- A61K 39/295: Polyvalent viral antigens (vaccinia virus or variola virus A61K39/285); Mixtures of viral and bacterial antigens
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/32634: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

## Claims

### Claim 1

A composition comprising
a) a first lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1, and
b) a second lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2.

### Claim 2 (depends on 1)

The composition according to claim 1, further comprising polysorbate-80, aluminum, histidine, and sodium chloride.

### Claim 3 (depends on 2)

The composition according to claim 2, wherein the composition comprises about 120 μg/ml of the first polypeptide; about 120 μg/ml of the second polypeptide; about 2.8 molar ratio of polysorbate-80; about 0.5 mg/ml aluminum; about 10 mM histidine;
and about 150 mM sodium chloride.

### Claim 4 (depends on 2)

The composition according to claim 2, wherein the composition comprises about 60 μg of the first polypeptide; about 60 μg of the second polypeptide; about 18 μg polysorbate-80; about 250 μg aluminum; about 780 μg histidine; and about 4380 μg sodium chloride, per 0.5 ml dose.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein the composition induces a bactericidal titer of serum immunoglobulin that is at least greater than 1-fold higher in a human after receiving the first dose than a bactericidal titer of serum immunoglobulin in the human prior to receiving the first dose, when measured under identical conditions in a serum bactericidal assay using human complement.

### Claim 6 (depends on 1)

The composition according to claim 1, wherein the composition induces a bactericidal titer of serum immunoglobulin that is at least 2-fold higher in a human after receiving the first dose than a bactericidal titer of serum immunoglobulin in the human prior to receiving the first dose, when measured under identical conditions in a serum bactericidal assay using human complement.

### Claim 7 (depends on 1)

The composition according to claim 1, wherein the composition induces a bactericidal titer of serum immunoglobulin that is at least 4-fold higher in a human after receiving the first dose than a bactericidal titer of serum immunoglobulin in the human prior to receiving the first dose, when measured under identical conditions in a serum bactericidal assay using human complement.

### Claim 8 (depends on 1)

The composition according to claim 1, wherein the composition induces a bactericidal titer of serum immunoglobulin that is at least 8-fold higher in a human after receiving the first dose than a bactericidal titer of serum immunoglobulin in the human prior to receiving the first dose, when measured under identical conditions in a serum bactericidal assay using human complement.

### Claim 9 (depends on 1)

The composition according to claim 1, wherein the composition does not further comprise a polypeptide having less than 100% sequence identity to SEQ ID NO: 1.

### Claim 10 (depends on 1)

The composition according to claim 1, wherein the first polypeptide has a total of 258 amino acids.

### Claim 11 (depends on 1)

The composition according to claim 1, wherein the first polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 3 at the N-terminus of the polypeptide.

### Claim 12 (depends on 1)

The composition according to claim 1, wherein the composition does not further comprise a polypeptide having less than 100% sequence identity to SEQ ID NO: 2.

### Claim 13 (depends on 1)

The composition according to claim 1, wherein the second polypeptide has a total of 261 amino acids.

### Claim 14 (depends on 1)

The composition according to claim 1, wherein the second polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 3 at the N-terminus of the polypeptide.

### Claim 15 (depends on 1)

The composition according to claim 1, wherein the composition comprises at most two lipidated polypeptides.

### Claim 16 (depends on 1)

The composition according to claim 1, wherein the first polypeptide consists of the amino acid sequence set forth in SEQ ID NO: 1.

### Claim 17 (depends on 1)

The composition according to claim 1, wherein the second polypeptide consists of the amino acid sequence set forth in SEQ ID NO: 2.

### Claim 18 (depends on 1)

The composition according to claim 1, wherein the composition does not comprise a hybrid protein.

### Claim 19 (depends on 1)

The composition according to claim 1, wherein the composition does not comprise a chimeric protein.

### Claim 20 (depends on 1)

The composition according to claim 1, wherein the composition does not comprise a fusion protein.

### Claim 21 (depends on 1)

The composition according to claim 1, wherein the composition is not lyophilized.

### Claim 22 (depends on 1)

The composition according to claim 1, wherein the composition is a liquid composition.
